Description
Anti-HBV Antibody, Non-Fucosylated (BioBet-246ZP) is a human monoclonal IgG1, λ antibody against HBV. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Hepatitis B reinfection in liver transplant patients
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced HBV antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
HBV
Alternative Names
Exbivirumab; hepex-b; 569658-80-6; 19.79.5; HbsAg; HBV; Major surface antigen
Involvement in Disease
Diseases associated with LHB include Hypogonadotropic Hypogonadism 23 Without Anosmia and Hypogonadism.
Related Pathways
Its related pathways are Integrin Pathway and Signaling by GPCR.
Function
Promotes spermatogenesis and ovulation by stimulating the testes and ovaries to synthesize steroids.
Field of research
Cancer antibody; Microbiology and Infectious Disease antibody
Post-translational modifications
1.Glycosylation at Asn50 2.Glycosylation from GlyConnect
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, λ
Antibody Clone
BioBet-246ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to HBV. Exbivirumab is a human monoclonal antibody developed for the treatment of hepatitis B infections.
Antibody Indication
Hepatitis B reinfection in liver transplant patients
Hepatitis B reinfection in liver transplant patients
